Abstract
Incorporation of novel agents into auto-SCT for patients with multiple myeloma has led to improvement in their outcomes. However, the effects of new drugs, either single or combined, on PBSC mobilization have not been fully evaluated, particularly in phase 3 clinical studies. We analyzed the impact of two novel agent-based induction treatments in patients enrolled in the GIMEMA MMY-3006 study comparing bortezomib, thalidomide and dexamethasone (VTD) versus thalidomide and dexamethasone (TD) in preparation for double auto-SCT. Results showed that a short-term induction therapy with VTD did not adversely affect CD34 + cell yields as compared with TD (9.75 vs 10.76 × 10 6 CD34 + cells/kg, P=0.220). For poor mobilizers (6 CD34 + cells/kg), 5-year rates of time to progression (TTP), progression-free survival (PFS) and overall survival (OS) were significantly shorter than for successful mobilizers (TTP:17 vs 48%, P+ cells. The number of collected PBSCs predicted better outcomes after auto-SCT and VTD overcame the negative impact of a poor stem cell mobilization.
| Original language | English |
|---|---|
| Pages (from-to) | 673-678 |
| Number of pages | 6 |
| Journal | Bone Marrow Transplantation |
| Volume | 50 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 8 2015 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
- Medicine(all)
Cite this
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. / Brioli, A.; Perrone, G.; Patriarca, F.; Pezzi, A.; Nobile, F.; Ballerini, F.; Motta, M. R.; Ronconi, S.; Tacchetti, P.; Catalano, L.; Zannetti, B. A.; Rizzi, S.; Volpe, S.; Zamagni, E.; Liberati, A. M.; Mancuso, K.; Boccadoro, M.; Davies, F. E.; Morgan, G. J.; Palumbo, A.; Cavo, M.
In: Bone Marrow Transplantation, Vol. 50, No. 5, 08.05.2015, p. 673-678.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation
AU - Brioli, A.
AU - Perrone, G.
AU - Patriarca, F.
AU - Pezzi, A.
AU - Nobile, F.
AU - Ballerini, F.
AU - Motta, M. R.
AU - Ronconi, S.
AU - Tacchetti, P.
AU - Catalano, L.
AU - Zannetti, B. A.
AU - Rizzi, S.
AU - Volpe, S.
AU - Zamagni, E.
AU - Liberati, A. M.
AU - Mancuso, K.
AU - Boccadoro, M.
AU - Davies, F. E.
AU - Morgan, G. J.
AU - Palumbo, A.
AU - Cavo, M.
PY - 2015/5/8
Y1 - 2015/5/8
N2 - Incorporation of novel agents into auto-SCT for patients with multiple myeloma has led to improvement in their outcomes. However, the effects of new drugs, either single or combined, on PBSC mobilization have not been fully evaluated, particularly in phase 3 clinical studies. We analyzed the impact of two novel agent-based induction treatments in patients enrolled in the GIMEMA MMY-3006 study comparing bortezomib, thalidomide and dexamethasone (VTD) versus thalidomide and dexamethasone (TD) in preparation for double auto-SCT. Results showed that a short-term induction therapy with VTD did not adversely affect CD34 + cell yields as compared with TD (9.75 vs 10.76 × 10 6 CD34 + cells/kg, P=0.220). For poor mobilizers (6 CD34 + cells/kg), 5-year rates of time to progression (TTP), progression-free survival (PFS) and overall survival (OS) were significantly shorter than for successful mobilizers (TTP:17 vs 48%, P+ cells. The number of collected PBSCs predicted better outcomes after auto-SCT and VTD overcame the negative impact of a poor stem cell mobilization.
AB - Incorporation of novel agents into auto-SCT for patients with multiple myeloma has led to improvement in their outcomes. However, the effects of new drugs, either single or combined, on PBSC mobilization have not been fully evaluated, particularly in phase 3 clinical studies. We analyzed the impact of two novel agent-based induction treatments in patients enrolled in the GIMEMA MMY-3006 study comparing bortezomib, thalidomide and dexamethasone (VTD) versus thalidomide and dexamethasone (TD) in preparation for double auto-SCT. Results showed that a short-term induction therapy with VTD did not adversely affect CD34 + cell yields as compared with TD (9.75 vs 10.76 × 10 6 CD34 + cells/kg, P=0.220). For poor mobilizers (6 CD34 + cells/kg), 5-year rates of time to progression (TTP), progression-free survival (PFS) and overall survival (OS) were significantly shorter than for successful mobilizers (TTP:17 vs 48%, P+ cells. The number of collected PBSCs predicted better outcomes after auto-SCT and VTD overcame the negative impact of a poor stem cell mobilization.
UR - http://www.scopus.com/inward/record.url?scp=84928924087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928924087&partnerID=8YFLogxK
U2 - 10.1038/bmt.2014.322
DO - 10.1038/bmt.2014.322
M3 - Article
C2 - 25642764
AN - SCOPUS:84928924087
VL - 50
SP - 673
EP - 678
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 5
ER -